172 related articles for article (PubMed ID: 31610441)
1. Systemic bevacizumab for end-stage juvenile recurrent respiratory papillomas: A case report.
Hamdi O; Dome J; Zalzal G; Preciado D
Int J Pediatr Otorhinolaryngol; 2020 Jan; 128():109706. PubMed ID: 31610441
[TBL] [Abstract][Full Text] [Related]
2. Systemic bevacizumab for recurrent respiratory papillomatosis.
Baday YI; Ongkasuwan J; Venkatramani R
Int J Pediatr Otorhinolaryngol; 2020 Nov; 138():110352. PubMed ID: 32906078
[TBL] [Abstract][Full Text] [Related]
3. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Institution's Experience.
So RJ; Rayle C; Joo HH; Huang EY; Seiwert TY; Raabe EH; Best SR
Laryngoscope; 2024 Jul; 134(7):3253-3259. PubMed ID: 38525973
[TBL] [Abstract][Full Text] [Related]
4. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases.
Bedoya A; Glisinski K; Clarke J; Lind RN; Buckley CE; Shofer S
Am J Case Rep; 2017 Jul; 18():842-846. PubMed ID: 28757601
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement.
So RJ; Hidalgo Lopez JC; Ballestas SA; Klein AM; Steuer C; Shin DM; Abousaud M; Teng Y; Saba NF; Tkaczuk AT; Schaefer ES; Seiwert TY; McClellan K; Best SR
Laryngoscope; 2024 Feb; 134(2):577-581. PubMed ID: 37470254
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Follow-Up on Systemic Bevacizumab Treatment in Recurrent Respiratory Papillomatosis.
Evers G; Schliemann C; Beule A; Schmidt LH; Schulze AB; Kessler C; Hoffmann TK; Wiewrodt R; Groll AH; Bleckmann A; Rudack C; Berdel WE; Mohr M
Laryngoscope; 2021 Jun; 131(6):E1926-E1933. PubMed ID: 33382105
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of bevacizumab and cidofovir treatment in HPV-associated recurrent respiratory papillomatosis - review of the literature.
Jackowska J; Piersiala K; Klimza H; Wierzbicka M
Otolaryngol Pol; 2018 Jun; 72(4):1-8. PubMed ID: 30190442
[TBL] [Abstract][Full Text] [Related]
8. Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey.
Best SR; Mohr M; Zur KB
Laryngoscope; 2017 Oct; 127(10):2225-2229. PubMed ID: 28657692
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review.
Pogoda L; Ziylan F; Smeeing DPJ; Dikkers FG; Rinkel RNPM
Eur Arch Otorhinolaryngol; 2022 Sep; 279(9):4229-4240. PubMed ID: 35462578
[TBL] [Abstract][Full Text] [Related]
10. Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children.
Carnevale C; Ferrán-De la Cierva L; Til-Pérez G; Peña-Zarza JA; Osona-Rodriguez B; Martinez-Lozano J; Sarría-Echegaray P; Arancibia-Tagle D; Tomás-Barberán M
Laryngoscope; 2019 Apr; 129(4):1001-1004. PubMed ID: 30588638
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in an infant.
Gates C; Tomboc P; Allison A; Carr M
Int J Pediatr Otorhinolaryngol; 2020 Feb; 129():109762. PubMed ID: 31707187
[TBL] [Abstract][Full Text] [Related]
12. Systemic bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in children: A series of three pediatric cases and literature review.
Enrique OH; Eloy SH; Adrian TP; Perla V
Am J Otolaryngol; 2021; 42(5):103126. PubMed ID: 34175693
[TBL] [Abstract][Full Text] [Related]
13. Recurrent Respiratory Papillomatosis With Complete Response to Systemic Bevacizumab Therapy.
Gorelik D; Frantz A; Dome JS; Reilly BK
Ear Nose Throat J; 2024 Feb; 103(2):100-101. PubMed ID: 34392730
[TBL] [Abstract][Full Text] [Related]
14. Renal Implications of Long-Term Systemic Bevacizumab for Recurrent Respiratory Papillomatosis.
Robinson CH; Hart-Matyas M; Morgenstern DA; Noone D; Campisi P
Ann Otol Rhinol Laryngol; 2024 Jan; 133(1):119-123. PubMed ID: 37439024
[TBL] [Abstract][Full Text] [Related]
15. Local Bevacizumab Treatment of Juvenile-Onset Respiratory Papillomatosis Might Induce Multiple Tracheal Pyogenic Granulomas.
Zeleník K; Komínek P; Staníková L; Formánek M
Laryngoscope; 2021 Feb; 131(2):E518-E520. PubMed ID: 32633817
[No Abstract] [Full Text] [Related]
16. Long-Term Follow-up of Parenteral Bevacizumab In Patients with Recurrent Respiratory Papillomatosis.
Ballestas SA; Hidalgo Lopez J; Klein AM; Steuer C; Shin DM; Abousaud M; Schmitt NC; Teng Y; Saba NF; Tkaczuk AT
Laryngoscope; 2023 Oct; 133(10):2725-2733. PubMed ID: 36815602
[TBL] [Abstract][Full Text] [Related]
17. Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis: Long-Term Follow-Up.
Ruiz R; Balamuth N; Javia LR; Zur KB
Laryngoscope; 2022 Oct; 132(10):2071-2075. PubMed ID: 35043981
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child.
Zur KB; Fox E
Laryngoscope; 2017 Jul; 127(7):1538-1542. PubMed ID: 27996119
[TBL] [Abstract][Full Text] [Related]
19. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis.
Sidell DR; Nassar M; Cotton RT; Zeitels SM; de Alarcon A
Ann Otol Rhinol Laryngol; 2014 Mar; 123(3):214-21. PubMed ID: 24633948
[TBL] [Abstract][Full Text] [Related]
20. Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population.
Tkaczuk A; Trivedi S; Mody MD; Steuer CE; Shin DM; Klein AM; Saba NF
Laryngoscope; 2021 Mar; 131(3):E921-E928. PubMed ID: 33107615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
